Invirase

Medicinal Chemistry is often referred to as a mature science. We believe that this is a misperception. What is probably more… Expand

Saquinavir is a selective HIV protease inhibitor with limited systemic bioavailability (4% for the hard gelatin capsule (Invirase… Expand

AIMS Bioavailability of orally administered drugs depends on several factors including active excretion, e.g. by P-glycoprotein… Expand

Two studies, concerning the synthesis of original nucleoside analogs regarded as an application of heterochemistry on… Expand

Cytochrome P450 3A4 (CYP3A4), the major phase I drug metabolizing enzyme in humans, and the MDR1 gene product P-glycoprotein (P… Expand

The humoral immune response to HIV infection plays an important role in determining disease progression. Few and discordant… Expand

In 1995 and 1996, the Food and Drug Administration (FDA) approved three products in the new protease inhibitor class of drugs… Expand

The Food and Drug Administration (FDA) approved two new protease inhibitors--ritonavir and indinavir--for the treatment of HIV… Expand

Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the… Expand

: Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the… Expand